PharmiWeb.com - Global Pharma News & Resources
11-Jul-2019

Acute Repetitive Seizures Market Size to Cross USD 4 Billion by 2026

The Global Acute Repetitive Seizures Market Size projected to register USD 4 billion by 2026, registering at a CAGR growth of 48.6% over the forecast period 2018 to 2026. Increase in the numeral of initiatives to surge the consciousness about epilepsy is the main parameter boosting the acute repetitive seizures market.

High unmet clinical demand for patients, as well as caregivers, and accessibility of progressive product pipeline are some of the main factors anticipated to push industry development. Drug therapy is operative for many of the patients suffering from cluster seizures. Though, there are an important numeral of treatment challenges and unmet medical demand such as drug induced seizures, adverse reactions, and lack of ant epileptogenic agents that can prevent growth of seizures and its comorbidities.

The acute repetitive seizures market is presently led by generic drugs which mainly comprise oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the single approved drug for usage in U.S. and buccal midazolam in European Union. Other medicines, for instance, midazolam (intramuscular, buccal, intranasal,), diazepam (intramuscular and oral), progesterone and lorazepam (intranasal, oral, sublingual) and are mainly used off label. The industry is anticipated to be combined with some major businesses and high market chunk in terms of revenue.

Download Report Sample Pages For Better Understanding Study at https://www.acumenresearchandconsulting.com/request-sample/968

Additionally, in an effort to curb healthcare expenditure, governments are construction constant labours to decrease hospital stays and on-site treatment costs via casualty care models, for instance, clinic and home healthcare. Developing nations such as China and India, are progressively applying such healthcare reform, which is anticipated to push the growth of acute repetitive seizures market.

There are numerous routes of drug administration; out of which, nasal route is the most chosen over others, for instance, rectal, buccal, and parenteral. The buccal route is favoured by caregivers and parents for children suffering from paediatric seizures since pill can be administered even outside the hospital.

The global acute repetitive seizures market is segmented into product, and region. On the basis of product the global acute repetitive seizures market is segmented into USL-261, Neurelis-1, AZ-002, Diastat Rectal Gel, and Others. On the basis of region the global Acute Repetitive Seizures market is segmented into Latin America, Europe, Asia Pacific, North America, and Middle East amp; Africa.

Diastat rectal gel was the foremost product sub-segment in 2018 owing to effectiveness of the route of administration and affordability of the product. USL-261 is anticipated to observer a profitable CAGR over the forecast timeframe. USL-21 has an edge over the other medicines due to its superior clinical profile and positive phase III results.

North America captures the largest share in 2018 owing to parameters, for instance, rising initiatives for rising consciousness around epilepsy and seizures. Germany is expected to observer profitable development over the next decade due to technical progressions in clinical, scientific, and medical fields.

North America Acute Repetitive Seizures market is expected to lead the global market throughout the forecast period attributable to existence of prominent number of market players and high incidence of infectious and chronic diseases. The Asia Pacific acute repetitive seizures market is expected to increase at the considerable CAGR during the forecast period. Dense population along with increasing incidences of chronic diseases such as diabetes and cancer are the major factors boosting to the growth of the regional market.

The key players catering to the global acute repetitive seizures market are Alexza Pharmaceuticals, Inc., Neurelis, Inc., and UCB S.A. The global players are continuously investing in Ramp;D and innovating new product portfolio to attract more and more business opportunity from the emerging nation such as India and China. Also, Increasing Ramp;D investments coupled with technological advancements to commercialise highly efficient products are anticipated to offer lucrative opportunities for industry participants. Neurelis, Inc. and UCB S.A. are expected to captures the major share of the global acute repetitive seizures market owing to the commercialization of VALTOCO and USL-261. As both the drugs (USL-261 and VALTOCO) are granted orphan drug designation, the values and price will be usually high. Also, according the studies, the preferred route of administration is nasal, which in turn will result into advanced acceptance of these two drugs.

View Detail Report at https://www.acumenresearchandconsulting.com/acute-repetitive-seizures-market

TABLE OF CONTENT

Chapter 1. Industry Overview

1.1 Definition and Scope
1.1.1 Definition of Acute Repetitive Seizures
1.1.2 Market Segmentation
1.2 Summary
1.2.1 Market Snapshot
1.2.2 Acute Repetitive Seizures Market, By Product
1.2.2.1 Global Acute Repetitive Seizures Market Revenue (USD Million) Comparison, By Product (2016-2026)
1.2.2.2 Global Acute Repetitive Seizures Market Revenue (USD Million)Share, By Product in 2026
1.2.2.3 USL-261
1.2.2.4 NRL-1
1.2.2.5 AZ-002
1.2.2.6 Diastat Rectal Gel
1.2.3 Acute Repetitive Seizures Market by Geography
1.2.3.1 Global Acute Repetitive Seizures Market Revenue (USD Million) and Growth Rate Comparison by Geography (2016-2026)
1.2.3.2 North America Acute Repetitive Seizures Market Revenue (USD Million) (2016-2026)
1.2.3.3 Europe Acute Repetitive Seizures Market Revenue (USD Million) (2016-2026)
1.2.3.4 Asia-Pacific Acute Repetitive Seizures Market Revenue (USD Million) (2016-2026)
1.2.3.5 Latin America Acute Repetitive Seizures Market Revenue (USD Million) (2016-2026)
1.2.3.6 Middle East Acute Repetitive Seizures Market Revenue (USD Million)(2016-2026)
1.2.3.7 Africa Acute Repetitive Seizures Market Revenue (USD Million) and Growth Rate (2016-2026)

Chapter 2. Market Dynamics and Competition Analysis

2.1 Market Drivers
2.1.1 Increasing prevalence of neurological diseases
2.1.2 Strong pipeline products and the increasing number of regulatory approvals
2.2 Restraints and Challenges
2.2.1 Lack of awareness pertinent to the management of acute repetitive seizures
2.3 Growth Opportunities
2.3.1 The shift from rectal to the nasal route of administration
2.4 Porterrsquo;s Five Forces Analysis
2.4.1 Bargaining Power of Suppliers
2.4.2 Bargaining Power of Buyers
2.4.3 Threat of Substitute
2.4.4 Threat of New Entrants
2.4.5 Degree of Competition
2.5 Value Chain Analysis
2.6 Pipeline Drug Analysis of Acute Repetitive Seizures
2.6.1 Raw Material and Suppliers
2.6.2 Manufacturing Process Analysis
2.7 Regulatory Compliance
2.8 Competitive Landscape, 2017
2.8.1 Player Positioning Analysis
2.8.2 Key Strategies Adopted By Leading Players

Chapter 3. Manufacturing Plants Analysis

3.1 Manufacturing Plants Distribution of Global Acute Repetitive Seizures Major Manufacturers in 2017
3.2 Ramp;D Status and Technology Source of Global Acute Repetitive Seizures Major Manufacturers in 2017
3.3 Raw Materials Sources Analysis of Global Acute Repetitive Seizures Major Manufacturers in 2017

Chapter 4. Acute Repetitive Seizures Market By Product

4.1 Global Acute Repetitive Seizures Revenue (USD Million), By Product
4.2 USL-261
4.2.1 Market Revenue (USD Million) and Growth Rate, 2016 - 2026
4.2.2 USD-261 Market Revenue (USD Million) and Forecast, By Region, 2016 - 2026
4.3 NRL-1
4.3.1 Market Revenue (USD Million) and Growth Rate, 2016ndash;2026
4.3.2 NRL-1 Market Revenue (USD Million) and Forecast, By Region, 2016 - 2026
4.4 AZ-002
4.4.1 Market Revenue (USD Million) and Growth Rate, 2016 - 2026
4.4.2 AZ-002 Market Revenue (USD Million) and Forecast, By Region, 2016 - 2026
4.5 Diastat Rectal Gel
4.5.1 Market Revenue (USD Million) and Growth Rate, 2016 - 2026
4.5.2 Diastat Rectal GelMarketRevenue (USD Million) and Forecast, By Region, 2016 - 2026
4.6 Others
4.6.1 Market Revenue (USD Million) and Growth Rate, 2016 - 2026
4.6.2 Other Market Revenue (USD Million) and Forecast, By Region, 2016 - 2026

Chapter 5. North America Acute Repetitive Seizures Market By Country

5.1 North America Acute Repetitive Seizures Market Revenue (USD Million), 2016 - 2026
5.2 North America Acute Repetitive Seizures Market Revenue (USD Million) Share Comparison, 2016amp; 2026 (%)
5.3 U.S.
5.3.1 U.S. Acute Repetitive Seizures Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
5.4 Canada
5.4.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
5.5 Mexico
5.5.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026

Chapter 6. Europe Acute Repetitive Seizures Market, By Country

6.1 Europe Acute Repetitive Seizures Market Revenue (USD Million), 2016 - 2026
6.2 Europe Acute Repetitive Seizures Market Revenue (USD Million) Share Comparison, 2016amp; 2026 (%)
6.3 UK
6.3.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
6.4 Germany
6.4.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
6.5 France
6.5.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
6.6 Rest of Europe
6.6.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026

Chapter 7. Asia-Pacific Acute Repetitive Seizures Market, By Country

7.1 Asia-Pacific Acute Repetitive Seizures Market Revenue (USD Million), 2016 - 2026
7.2 Asia Pacific Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
7.3 China
7.3.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
7.4 Japan
7.4.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
7.5 India
7.5.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
7.6 Australia
7.6.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
7.7 South Korea
7.7.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
7.8 Rest of Asia-Pacific
7.8.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026

Chapter 8. Latin America Acute Repetitive Seizures Market, By Country

8.1 Latin America Acute Repetitive Seizures Market Revenue (USD Million), by Country, 2016 - 2026
8.2 Latin America Acute Repetitive Seizures Market Revenue (USD Million), by Product, 2016 - 2026
8.3 Latin America Acute Repetitive Seizures Market Revenue (USD Million) Share Comparison, 2016amp; 2026 (%)
8.4 Brazil
8.4.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
8.5 Argentina
8.5.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
8.6 Rest of Latin America
8.6.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026

Chapter 9. Middle East Acute Repetitive Seizures Market, By Country

9.1 Middle East Acute Repetitive Seizures Market Revenue (USD Million), By Country,2016 - 2026
9.2 Middle East Acute Repetitive Seizures Market Revenue (USD Million), By Product, 2016 - 2026
9.3 Middle East Acute Repetitive Seizures Market Revenue (USD Million) Share Comparison, 2016amp; 2026 (%)
9.4 Saudi Arabia
9.4.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
9.5 UAE
9.5.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
9.6 Rest of Middle East
9.6.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026

Chapter 10. Africa Acute Repetitive Seizures Market By Country

10.1 Africa Acute Repetitive Seizures Market Revenue (USD Million), By Region, 2016 - 2026
10.2 Africa Acute Repetitive Seizures Market Revenue (USD Million), By Product, 2016 - 2026
10.3 Africa Acute Repetitive Seizures Market Revenue (USD Million) Share Comparison, 2016 amp; 2026 (%)
10.4 South Africa
10.4.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
10.5 Egypt
10.5.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026
10.6 Rest of Africa
10.6.1 Market Revenue (USD Million) and Forecast, By Product, 2016 - 2026

Chapter 11. Company Profile

11.1 Grupo Ferrer Internacional S.A. (ALEXZA)
11.1.1 Company Overview
11.1.2 Financial Performance
11.1.3 Pipeline Analysis
11.1.4 Recent Development
11.1.5 Strategies
11.2 Neurelis, Inc.
11.2.1 Company Overview
11.2.2 Financial Performance
11.2.3 Pipeline Analysis
11.2.4 Recent Developments
11.2.5 Strategies
11.3 UCB S.A.
11.3.1 Company Snapshot
11.3.2 Overview
11.3.3 Financial Overview, 2015-2017, (USD MILLION
11.3.1 Ramp;D Investment
11.3.2 Pipeline Analysis
11.3.3 Key Developments
11.3.4 Strategies

Chapter 12. Research Approach

12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.2 Market Size Estimation
12.3 Market Breakdown and Data Triangulation
12.4 Data Source
12.4.1 Secondary Sources
12.5 Primary Sources
12.6 Report Scope

INQUIRY BEFORE BUYING: https://www.acumenresearchandconsulting.com/inquiry-before-buying/968

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/968

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 11-Jul-2019